COST EFFECTIVENESS OF ZOLEDRONIC ACID VS. PAMIDRONATE OR NO THERAPY FOR THE TREATMENT OF BONE METASTASES SECONDARY TO PROSTATE CANCER

被引：0
|
作者：
Carter, J. A. [1 ]
Bains, M. [2 ]
Chandiwana, D. [2 ]
Kaura, S. [3 ]
Botteman, M. F. [1 ]
机构：
[1] Pharmerit N Amer LLC, Bethesda, MD USA
[2] Novartis Pharmaceut UK Ltd, Camberley, Surrey, England
[3] Novartis Pharmaceut, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1174
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A447 / A447
页数：1
相关论文
共 50 条
  • [1] STUDY OF COST-EFFECTIVENESS AND BUDGETARY IMPACT OF DENOSUMAB VS. ZOLEDRONIC ACID FOR THE HANDLING OF BONE METASTASES IN PATIENTS WITH PROSTATE CANCER IN COLOMBIA
    Perez, M.
    Garcia Perlaza, J.
    Fletscher, P. M.
    Vargas-Valencia, J.
    VALUE IN HEALTH, 2017, 20 (09) : A876 - A876
  • [2] Zoledronic acid compared with pamidronate in patients with prostate cancer and bone metastases: Effects on skeletal complications and bone markers
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 57 - 57
  • [3] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE
    Meijboom, M.
    Botteman, M.
    Kaura, S.
    Durand-Zaleski, I.
    ANNALS OF ONCOLOGY, 2008, 19 : 201 - 201
  • [4] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, M.
    Botteman, M. F.
    Kaura, S.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 132 - 132
  • [5] Cost-effectiveness of oral ibandronate versus iv zoledronic acid or iv pamidronate in the treatment of breast cancer with bone metastases in patients undergoing iv chemotherapy in the UK
    De Cock, E
    Hutton, J
    Barrett-Lee, P
    Canney, P
    Body, JJ
    Neary, M
    Lewis, GJ
    VALUE IN HEALTH, 2004, 7 (06) : 672 - 672
  • [6] Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
    Koo, Kaitlin
    Lam, Kinsey
    Mittmann, Nicole
    Konski, Andre
    Dennis, Kristopher
    Zeng, Liang
    Lam, Henry
    Chow, Edward
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1785 - 1791
  • [7] Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases
    Kaitlin Koo
    Kinsey Lam
    Nicole Mittmann
    Andre Konski
    Kristopher Dennis
    Liang Zeng
    Henry Lam
    Edward Chow
    Supportive Care in Cancer, 2013, 21 : 1785 - 1791
  • [8] Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom
    De Cock, E
    Hutton, J
    Canney, P
    Body, JJ
    Barrett-Lee, P
    Neary, MP
    Lewis, G
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1295 - 1310
  • [9] Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases
    Feng Wang
    Wei Chen
    Hongde Chen
    Licai Mo
    Haiyong Jin
    Zhixian Yu
    Chengdi Li
    Qing Liu
    Feifei Duan
    Zhiliang Weng
    Medical Oncology, 2013, 30
  • [10] Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases
    Wang, Feng
    Chen, Wei
    Chen, Hongde
    Mo, Licai
    Jin, Haiyong
    Yu, Zhixian
    Li, Chengdi
    Liu, Qing
    Duan, Feifei
    Weng, Zhiliang
    MEDICAL ONCOLOGY, 2013, 30 (03)
12345